2025 Europe Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 Europe Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in ALS treatment development in Europe are Mitsubishi Tanabe Pharma Corporation, Biogen, Sanofi, and F. Hoffmann-La Roche AG. Mitsubishi Tanabe is a major player offering Radicava (edaravone), a key ALS drug, and recently transferred its European argatroban business to focus on ALS treatments. Biogen is notable for developing Tofersen, a gene-targeting therapy for SOD1 mutation ALS, which received orphan drug designation from the EMA. Sanofi markets Rilutek (riluzole), the first approved ALS drug shown to modestly prolong survival. Hoffmann-La Roche is involved in ALS medication development and clinical trials across Europe.
Additionally, European biotech companies like Axoltis Pharma are advancing novel candidates such as NX210c, a peptide promoting neuroprotection and blood-brain barrier repair, currently in phase 2 trials. Collaborative research initiatives like the TRICALS network unite over 60 ALS centers across Europe to accelerate clinical drug development and improve trial quality. These efforts reinforce Europe's leading role in ALS therapeutic innovation and clinical research infrastructure.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in ALS treatment development in Europe are Mitsubishi Tanabe Pharma Corporation, Biogen, Sanofi, and F. Hoffmann-La Roche AG. Mitsubishi Tanabe is a major player offering Radicava (edaravone), a key ALS drug, and recently transferred its European argatroban business to focus on ALS treatments. Biogen is notable for developing Tofersen, a gene-targeting therapy for SOD1 mutation ALS, which received orphan drug designation from the EMA. Sanofi markets Rilutek (riluzole), the first approved ALS drug shown to modestly prolong survival. Hoffmann-La Roche is involved in ALS medication development and clinical trials across Europe.
Additionally, European biotech companies like Axoltis Pharma are advancing novel candidates such as NX210c, a peptide promoting neuroprotection and blood-brain barrier repair, currently in phase 2 trials. Collaborative research initiatives like the TRICALS network unite over 60 ALS centers across Europe to accelerate clinical drug development and improve trial quality. These efforts reinforce Europe's leading role in ALS therapeutic innovation and clinical research infrastructure.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
